Pancreatic Neuroendocrine Carcinoma

Observed

→ investigated in trials for

Temozolomidesmall_molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall_molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall_molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall_molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vatalanibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afliberceptother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall_molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall_molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cixutumumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dovitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall_molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gefitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lutetium (177lu) Oxodotreotideother

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Palbociclibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Regorafenibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Romidepsinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sapanisertibsmall_molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Pancreatic Neuroendocrine Carcinoma studied in …STUDIED_INderived10 of 37show all (up to 200)
→ studied in	NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05247905Phase 2 · active not recruiting Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial · condition mapped CURATED_BROADER · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02595424Phase 2 · active not recruiting Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01365169NA · recruiting Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00113360Phase 2 · completed RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma · condition mapped ALIAS · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05988918Phase 2 · active not recruiting Multicenter Trial of ESK981 in Patients With Select Solid Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00830557recruiting Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02230176Phase 2 · completed Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03736720Phase 2 · terminated Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin · condition mapped CURATED_BROADER · 37 trials mapped (6 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →

Pancreatic Neuroendocrine Carcinoma studied in …STUDIED_INderived10 of 37show all (up to 200)

→ studied in

NCT01824875Phase 2 · completed

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT05247905Phase 2 · active not recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial · condition mapped CURATED_BROADER · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT02595424Phase 2 · active not recruiting

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT01365169NA · recruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT00113360Phase 2 · completed

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma · condition mapped ALIAS · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT02834013Phase 2 · active not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT05988918Phase 2 · active not recruiting

Multicenter Trial of ESK981 in Patients With Select Solid Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT00830557recruiting

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT02230176Phase 2 · completed

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II · condition mapped ONTOLOGY_EXACT · 37 trials mapped (6 active)

—

Observed

→ studied in

NCT03736720Phase 2 · terminated

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin · condition mapped CURATED_BROADER · 37 trials mapped (6 active)

—

Observed